[go: up one dir, main page]

SG11201908980PA - Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells - Google Patents

Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Info

Publication number
SG11201908980PA
SG11201908980PA SG11201908980PA SG11201908980PA SG 11201908980P A SG11201908980P A SG 11201908980PA SG 11201908980P A SG11201908980P A SG 11201908980PA SG 11201908980P A SG11201908980P A SG 11201908980PA
Authority
SG
Singapore
Prior art keywords
cells
international
car
polyfunctional
pct
Prior art date
Application number
Inventor
John Rossi
Adrian Bot
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of SG11201908980PA publication Critical patent/SG11201908980PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)

Abstract

ANTICD CAR scFv (FMC63) HINGE/ TRANSMEMBRANE BLOOD CELLS REMOVED FROM PATIENT SIGNAL 2: CD28 GENETIC MODIFICATION OFT CELLS FIG. 1A SIGNAL 1: CD31; 4RE-INF6ON, CAR-T PRODUCT BIOMARKER PATIENT RECEIVES ANALYSIS CAR-T CELLS FIG. 1B CAR-T CELLS El 0 El 0 0 0 0 00 ▪ CO O 0 030 FIG. 1C K562-CD19 K562-NGFR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT onolomolmomll Ammo oimIE (10) International Publication Number WO 2018/187332 Al N co C (51) International Patent Classification: A61K 39/00 (2006.01) GO1N 33/50 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/025888 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,003 03 April 2017 (03.04.2017) US (71) Applicant: KITE PHARMA, INC. [US/US]; 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (72) Inventors: ROSSI, John, M.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). BOT, Adrian, I.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). (74) Agent: BARBIC, Andrej et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T = CELLS 1 -1 (57) : The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric re- ceptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining \" an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient. [Continued on next page] WO 2018/187332 Al MIDEDIMOHNOREEMOMOMINIMOIIIMEHOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201908980P 2017-04-03 2018-04-03 Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells SG11201908980PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481003P 2017-04-03 2017-04-03
PCT/US2018/025888 WO2018187332A1 (en) 2017-04-03 2018-04-03 Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Publications (1)

Publication Number Publication Date
SG11201908980PA true SG11201908980PA (en) 2019-10-30

Family

ID=62116944

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908980P SG11201908980PA (en) 2017-04-03 2018-04-03 Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
SG10201912624VA SG10201912624VA (en) 2017-04-03 2018-04-03 Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912624VA SG10201912624VA (en) 2017-04-03 2018-04-03 Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Country Status (12)

Country Link
US (2) US11357796B2 (en)
EP (1) EP3655022A1 (en)
JP (2) JP2020512983A (en)
KR (2) KR20190130024A (en)
CN (1) CN110494158A (en)
AR (1) AR111360A1 (en)
AU (2) AU2018250148B2 (en)
CA (1) CA3057880A1 (en)
IL (1) IL269629A (en)
SG (2) SG11201908980PA (en)
TW (1) TW201902493A (en)
WO (1) WO2018187332A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018334279A1 (en) * 2017-09-15 2020-04-02 Kite Pharma, Inc. Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
CN112512537A (en) 2018-06-01 2021-03-16 凯德药业股份有限公司 Chimeric antigen receptor T cell therapy
EP3887978A4 (en) 2018-11-29 2022-08-17 Vineti Inc. Centralized and decentralized individualized medicine platform
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
CN111690730B (en) * 2019-03-14 2024-02-09 中国科学院上海巴斯德研究所 Application of IL-8 positive initial T cell as target for diagnosing thymus placeholder disease
CA3154819A1 (en) * 2019-10-16 2021-04-22 I. Caroline LE POOLE Materials and methods for treating vitiligo
CN115335508A (en) 2020-01-23 2022-11-11 康干细胞生物科技有限公司 Finished stem cells and immune cells, and pharmaceutical composition containing same
BR112022021020A2 (en) 2020-04-22 2023-02-14 Iovance Biotherapeutics Inc METHOD OF MANUFACTURING A CELL THERAPY PRODUCT, METHODS OF TREATMENT OF THE PATIENT WITH THE EXPANSION AND MANUFACTURED CELL THERAPY PRODUCT, AND, METHOD OF MANUFACTURING A CELL THERAPY PRODUCT
CN112063588A (en) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
EP1257632B1 (en) 2000-02-24 2007-09-12 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
CN106074601A (en) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 Method and composition for cellular immunotherapy
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
MX2014003176A (en) 2011-09-16 2015-08-05 Univ Pennsylvania T-CELLS DESIGNED BY ARN FOR CANCER TREATMENT.
CA2863799C (en) 2012-02-22 2020-09-01 Matthew J. FRIGAULT Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
DK3888674T3 (en) * 2014-04-07 2024-07-08 Novartis Ag TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
KR20230148387A (en) 2015-05-28 2023-10-24 카이트 파마 인코포레이티드 Diagnostic methods for t cell therapy
KR102349677B1 (en) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 How to Condition a Patient for T Cell Therapy
EP3510398A1 (en) * 2016-09-12 2019-07-17 Isoplexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics

Also Published As

Publication number Publication date
JP2022166297A (en) 2022-11-01
US20220265721A1 (en) 2022-08-25
AU2018250148A1 (en) 2019-10-17
KR20220144888A (en) 2022-10-27
AR111360A1 (en) 2019-07-03
US20180296601A1 (en) 2018-10-18
SG10201912624VA (en) 2020-02-27
TW201902493A (en) 2019-01-16
CN110494158A (en) 2019-11-22
US11357796B2 (en) 2022-06-14
AU2018250148B2 (en) 2021-09-23
AU2021250858A1 (en) 2021-11-04
WO2018187332A1 (en) 2018-10-11
IL269629A (en) 2019-11-28
KR20190130024A (en) 2019-11-20
CA3057880A1 (en) 2018-10-11
JP2020512983A (en) 2020-04-30
EP3655022A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
SG11201908980PA (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201805072PA (en) Nicotine powder delivery system
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201806542PA (en) Anti-mica antibodies
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201808125RA (en) Methods for solid tumor treatment
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases